A company developing treatments for drug-resistant bacterial infections is getting a boost from the Department of Defense.
Gaithersburg, Maryland-based Adaptive Phage Therapeutics, also known as APT, said Tuesday that it the DoD had awarded it $10.2 million to fund a clinical trial to develop its personalized bacteriophage therapeutic, PhageBank.
{iframe}https://medcitynews.com/2020/01/adaptive-phage-gets-10-from-dod-for-antibacterial-phage-therapies/?rf=1{/iframe}